Back to top

Analyst Blog

The independent Data Monitoring Committee (DMC) has recommended the continuation of Catalyst Pharmaceutical Partners, Inc.’s (CPRX - Snapshot Report) phase III study (n=36) on Firdapse. The randomized, double-blind, placebo-controlled, discontinuation study is evaluating Firdapse for the treatment of patients suffering from Lambert-Eaton myasthenic syndrome (LEMS).

The committee’s recommendation comes after reviewing the safety and clinical data from the study. Catalyst Pharma acquired the marketing rights to Firdapse from BioMarin Pharmaceutical Inc. (BMRN - Analyst Report) in Oct 2012 in the U.S., as per which the former is responsible for the above-mentioned phase III study.

In 2013, the U.S. Food and Drug Administration (FDA) granted ‘Breakthrough Therapy’ designation to Firdapse for the LEMS indication. The designation should help to speed up the development and review process of the candidate. Catalyst Pharma is leaving no stone unturned to ensure the successful completion of this phase III study.

Catalyst Pharma expects to complete enrolling patients for the study shortly. Top-line data from the study’s double-blind portion is anticipated in the third quarter of 2014. The company expects to seek FDA approval for Firdapse in the LEMS indication next year. We expect investor focus to remain on updates relating to the Firdapse development program.

Catalyst Pharma mentioned in its press release that Firdapse is the first and only approved drug in the EU for symptomatic treatment in adults suffering from LEMS. The drug is available in the EU since 2010 and is marketed there by BioMarin. Apart from Firdapse, Catalyst Pharma also has CPP-115 in its pipeline, being developed for multiple indications including infantile spasms and epilepsy.

Catalyst Pharma carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector include Questcor Pharmaceuticals and Shire (SHPG - Analyst Report). Both stocks hold a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
TRAVELCENTE… TA 11.84 +6.38%
BANCO DO BR… BDORY 14.74 +5.66%
AIR INDUSTR… AIRI 9.99 +4.15%
EQT MIDSTRM… EQM 98.14 +3.38%